The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV

Annals of Tropical Medicine and Parasitology

Volumn 97, Issue SUPPL. 1, 2003, Pages

  Lopez Velez R ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTILEISHMANIAL AGENT; PENTAMIDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LABORATORY TEST; LYMPHOCYTE COUNT; NONHUMAN; RELAPSE; RETROSPECTIVE STUDY; REVIEW; SECONDARY PREVENTION; SPAIN; SUPERINFECTION; T LYMPHOCYTE; TREATMENT FAILURE; VIRUS LOAD; VISCERAL LEISHMANIASIS;

HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA; RNA VIRUSES;

EID: 0345659210     PISSN: 00034983     EISSN: None     Source Type: Journal    
DOI: 10.1179/000349803225002615     Document Type: Review

References (29)

1. Alvar, J., Cañavate, C., Gutierrez-Solar, B., Jiménez, M., Laguna, F., López-Vélez, R., Molina, R. & Moreno, J. (1997). Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clinical Microbiology Reviews, 10, 298-319
2. Amador, C., Bodi, V., Pasquau, F., Ena, J., Benito, C. & Fenoll, V. (2001). Factores de riesgo asociados a la aparición de infecciones durante el primer aǹo de tratamiento antirretroviral de alta eficacia. Medicina Clinica, 116, 41-46.
3. Anon. (1999). Enfermedades de declaración obligatoria, 1998. Boletín Epidemiológico de la Comunidad de Madrid, 6, 11-31.
4. Berenguer, J., Cosin, J., Miralles, P., Lopez, J. C. & Padilla, B. (2000). Discontinuation of secondary anti-Leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS, 14, 2946-2948.
5. Casado, J., López-Vélez, R., Pintado, V., Antela, A., Quereda, C. & Moreno, S. (2001). Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy. European Journal of Clinical Microbiology and Infectious Diseases, 20, 202-205.
6. Clerici, M., Hakim, F. T., Venzon, D. J., Blatt, S., Hendrix, C. W., Wynn, T. A. & Shearer, G. M. (1993). Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. Journal of Clinical Investigation, 91, 759-765.
7. De la Rosa, R., Pineda, J. A., Delgado, J., Macías, J., Morillas, F., Martín-Sánchez, J., Leal, M., Sánchez-Quijano, A. & Lissen, E. (2001). Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases, 32, 633-635.
8. Di Giorgio, C., Faraut-Gambarelli, F., Imbert, A., Minodier, P., Gasquet, M. & Dumon, H. (1999). Flow cytometric assessment of amphotericin B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. Journal of Antimicrobial Chemotherapy, 44, 71-76.
9. Faraut-Gambarelli, F., Piarroux, R., Deniau, M., Giusiano, B., Marty, P., Michel, G., Faugere, B. & Dumon, H. (1997). In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrobial Agents and Chemotherapy, 41, 827-830.
10. Jiménez-Expósito, M., Alonso-Villaverde, C., Sardá, P. & Masana, L. (1999). Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-viral load after highly active antiretroviral therapy. AIDS, 13, 152-153.
11. Kubar, J., Marty, P., Lelievre, A., Quaranta, J. F., Staccini, P., Caroli-Bosc, C. & Le Fichoux, Y. (1998). Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS, 12, 2147-2153.
12. Laguna, F., Adrados, M., Alvar, J., Soriano, V., Valencia, M. E., Moreno, V., Polo, R., Verdejo, J., Jiménez, M. I., Martínez, P., Martínez, M. L. & González-Lahoz, J. M. (1997). Visceral leishmaniasis in patients infected with the human immunodeficiency virus. European Journal of Clinical Microbiology and Infectious Diseases, 16, 898-903.
13. Laguna, F., López-Vélez, R., Pulido, F., Salas, A., Torre-Cisneros, J., Torres, E., Medrano, F. J., Sanz, J., Pico, G., Gómez-Rodrigo, J., Pasquau, J. & Alvar, J. (1999). Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS, 13, 1063-1069.
14. López-Vélez, R., Pérez-Molina, J. A., Guerrero, A., Baquero, F., Villarrubia, J., Escribano, L., Bellas, C., Pérez-Corral, F. & Alvar, J. (1998). Clinico-epidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. American Journal of Tropical Medicine and Hygiene, 58, 436-443.
15. López-Vélez, R., Casado, J. & Pintado, V. (2001). Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART). Clinical Microbiology and Infection, 7, 394-395.
16. Mastroianni, C. M., d'Ettorre, G., Forcina, G., Corpolongo, A., dell'Isola, S., Lichtner, M., d'Agostino, C., Trinchieri, V., Santopadre, P. & Vullo, V. (2000). Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination anti-retroviral treatment: report of two cases. Journal of Infection, 40, 94-96.
17. Medrano, F. J., Rey, C., Leal, M., Cañavate, C., Rubio, A., Sánchez-Quijano, A., Alvar, J. & Lissen, E. (1998). Dynamics of serum cytokines in patients with visceral leishmaniasis and HIV-1 co-infection. Clinical and Experimental Immunology, 114, 403-407.
18. Miralles, P., Moreno, S., Pérez-Tascón, M., Cosín, J., Díaz, M. D. & Bouza, E. (1995). Fever of uncertain origin in patients infected with the human immunodeficiency virus. Clinical Infectious Diseases, 20, 872-875.
19. Nigro, L., Cacopardo, B., Preiser, W., Braner, J., Cinatl, J., Palermo, F., Russo, R., Doerr, H. W. & Nunnari, A. (1999). In vitro production of type 1 and type 2 cytokines by peripheral blood mono-nuclear cells from subjects coinfected with human immunodeficiency virus and Leishmania infantum. American Journal of Tropical Medicine and Hygiene, 60, 142-145.
20. Pérez-Molina, J. A., López-Vélez, R., Montilla, P. & Guerrero, A. (1996). Pentamidine isothionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS, 10, 237-238.
21. Pintado, V. & López-Vélez, R. (2001). HIV-associated visceral leishmaniasis. Clinical Microbiology and Infection, 7, 291-300.
22. Pintado, V., Martín-Rabadán, P., Rivera, M. L., Moreno, S. & Bouza, E. (2001). Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine, 80, 54-73.
23. Ribera, E., Ocaña, I., de Otero, J., Cortés, E., Gasser, I. & Pahissa, A. (1996). Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients. American Journal of Medicine, 100, 496-501.
24. Ridolfo, A. L., Gervasoni, C., Antinori, S., Pizzuto, M., Santambrogio, S., Trabattoni, D., Clerici, M. & Galli, M. (2000). Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. Journal of Infection, 40, 199-202.
25. Soriano, V., Dona, C., Rodríguez-Rosado, R., Barreiro, P. & González-Lahoz, J. (2000). Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active anti-retroviral therapy. AIDS, 14, 383-386.
26. Tumbarello, M., Tacconelli, E., Bertagnolio, S. & Cauda, R. (2000). Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. AIDS, 14, 2948-2950.
27. Villanueva, J., Alarcón, A., Bernabeu-Wittel, M., Cordero, E., Prados, D., Regordán, C. & Alvar, J. (2000). Prospective evaluation and follow-up of european patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy. European Journal of Clinical Microbiology and Infectious Diseases, 19, 798-801.
28. World Health Organization (1995). Report on the Consultative Meeting on Leishmania/HIV Co-infection. Document WHO/LEISH/95/1-14. Geneva: WHO.
29. World Health Organization (1999). Leishmania/HIV co-infection, south-western Europe, 1990-1998. Weekly Epidemiological Record, 74, 365-375.